Trade ALGS anytime, even after market hours
Regulated by
MAS
Trusted by
400,000+ users
Aligos Therapeutics, Inc. (ALGS) is trading at US$6.79, down 4.03% today as of Aug 28, 13:03 EDT. The company has a market capitalisation of US$41.65M. Over the past 52 weeks, ALGS has traded between US$3.98 and US$13.69. On Syfe you can trade ALGS with $0 commission and add it to your watchlist.
| Previous close | US$7.07 |
|---|---|
| Market cap | US$41.65M |
| 52-week range | US$3.98 – US$13.69 |
| Volume | 80.26K |
| Exchange | US |
Add to Watchlist
Set Price Alert
Aligos Therapeutics, Inc.
Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the provision of therapeutics for chronic liver diseases and viral infections. The firm is focused on the discovery and development of targeted antiviral therapies for chronic hepatitis B (CHB) and coronaviruses, as well as leveraging its expertise in liver diseases to create targeted therapeutics for nonalcoholic steatohepatitis (NASH). The company was founded by Lucinda Quan and Lawrence M. Blatt on February 5, 2018 and is headquartered in South San Francisco, CA.
Year: 2020
Aligos Therapeutics Completes Enrollment in Phase 2 Study of Potential Chronic Hepatitis B Treatment
Jul 13, 12:33 PM · MT Newswires
Aligos Gets $25 Million Upfront Payment From Licensing Deal
Jul 6, 8:34 PM · MT Newswires
Lake Street Initiates Aligos Therapeutics With Buy Rating, $45 Price Target
May 28, 12:04 PM · MT Newswires
Aligos Therapeutics, Inc. (ALGS) stock is trading at US$6.79, -4.03% from the previous close of US$7.07.
The market cap for Aligos Therapeutics, Inc. (ALGS) stock is approximately US$41.65M.
The 52-week high for Aligos Therapeutics, Inc. (ALGS) stock is US$13.69.
The 52-week low for Aligos Therapeutics, Inc. (ALGS) stock is US$3.98.
Aligos Therapeutics, Inc. (ALGS) does not currently pay a dividend.
Stay on top of ALGS
Price moves, news and earnings — straight to your inbox.
Est. order value
US$0.00
Snapshot
